Eagle Pharmaceuticals Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 1/6

Eagle PharmaceuticalsDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -17% zurückgegangen, während in der Branche Biotechs die Gewinne wachsen. Die Umsatzerlöse sind gewachsen mit einer durchschnittlichen Rate von 6.7% pro Jahr. Eagle Pharmaceuticals Die Eigenkapitalrendite des Unternehmens beträgt 4.7%, und die Nettomargen liegen bei 4.6%.

Wichtige Informationen

-17.0%

Wachstumsrate der Gewinne

-13.3%

EPS-Wachstumsrate

Biotechs Wachstum der Industrie	17.0%
Wachstumsrate der Einnahmen	6.7%
Eigenkapitalrendite	4.7%
Netto-Marge	4.6%
Letzte Ertragsaktualisierung	30 Jun 2023

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Oct 27

Eagle files for FDA nod to start trial of CAL02 for bacterial pneumonia

Oct 12

Eagle, Enalare get up to $50.3M US contract to develop ENA-001 for community drug overdose

Sep 27

Eagle Pharma did not infringe on Endo’s vasopressin patents – appeals court

Aug 18

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analysts Are More Bearish Than They Used To Be

Aug 15

Eagle Pharmaceuticals Non-GAAP EPS of $1.56 misses by $1.80, revenue of $74.1M misses by $42.79M

Aug 09

These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Jul 06

Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 42% Above Its Share Price

Apr 29

Is Eagle Pharmaceuticals (NASDAQ:EGRX) Using Too Much Debt?

Dec 16

Shareholders May Be Wary Of Increasing Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) CEO Compensation Package

Jul 06

Eagle Pharmaceuticals: A Potential Reopening Play

Jun 16

Eagle Pharmaceuticals EPS misses by $0.49, misses on revenue

May 10

Eagle Pharma's Treakisym RTD + rituximab OK'd in Japan for large b-cell lymphoma

Apr 30

Eagle Pharmaceuticals (NASDAQ:EGRX) Could Easily Take On More Debt

Apr 15

Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 55% Above Its Share Price

Mar 25

Aufschlüsselung der Einnahmen und Ausgaben

Wie Eagle Pharmaceuticals Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

NasdaqGM:EGRX Einnahmen, Ausgaben und Erträge (USD Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten	F&E-Ausgaben
30 Jun 23	258	12	103	36
31 Mar 23	267	-3	93	37
31 Dec 22	317	36	87	34
30 Sep 22	298	21	82	31
30 Jun 22	272	23	79	45
31 Mar 22	246	36	78	43
31 Dec 21	172	-9	75	51
30 Sep 21	179	6	76	57
30 Jun 21	189	18	75	38
31 Mar 21	183	14	76	36
31 Dec 20	188	12	79	31
30 Sep 20	186	5	80	33
30 Jun 20	177	-5	81	38
31 Mar 20	192	2	80	40
31 Dec 19	196	14	76	37
30 Sep 19	204	26	69	31
30 Jun 19	214	42	65	27
31 Mar 19	216	38	63	33
31 Dec 18	213	32	61	44
30 Sep 18	204	28	58	48
30 Jun 18	216	30	61	51
31 Mar 18	207	32	68	42
31 Dec 17	237	52	71	33
30 Sep 17	271	100	77	38
30 Jun 17	246	97	71	33
31 Mar 17	237	105	60	30
31 Dec 16	189	81	53	28
30 Sep 16	127	25	40	22
30 Jun 16	94	3	35	25
31 Mar 16	60	-18	28	27
31 Dec 15	66	3	20	28
30 Sep 15	54	-4	19	23
30 Jun 15	51	-3	17	22
31 Mar 15	51	2	14	21
31 Dec 14	20	-21	12	19
30 Sep 14	19	-20	9	17
30 Jun 14	17	-11	4	14
31 Mar 14	20	-9	3	11
31 Dec 13	18	-11	4	10
30 Sep 13	14	-10	5	10
30 Jun 13	10	-14	8	9

Qualität der Erträge: EGRX hat hohe Qualitätseinkünfte.

Wachsende Gewinnspanne: EGRXDie aktuellen Gewinnspannen (4.6%) sind niedriger als im letzten Jahr (8.4%).

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: EGRXDie Erträge des Unternehmens sind in den letzten 5 Jahren um 17% pro Jahr zurückgegangen.

Beschleunigtes Wachstum: EGRXDas Unternehmen hat im vergangenen Jahr ein negatives Gewinnwachstum verzeichnet, so dass es nicht mit seinem 5-Jahres-Durchschnitt verglichen werden kann.

Erträge im Vergleich zur Industrie: EGRX hatte im vergangenen Jahr ein negatives Gewinnwachstum (-47.6%), was einen Vergleich mit dem Branchendurchschnitt Biotechs (-14.4%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: EGRXDie Eigenkapitalrendite des Unternehmens (4.7%) wird als niedrig angesehen.

Eagle Pharmaceuticals Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Eagle Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Eagle Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Eagle Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Recent updates

Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

Eagle Pharmaceuticals, Inc. announced delayed 10-Q filing

Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K

Eagle Pharmaceuticals, Inc. announced delayed annual 10-K filing

Eagle Pharmaceuticals, Inc. Announces Board and Committee Changes

New minor risk - Financial data availability

Investor sentiment improves as stock rises 19%

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Eagle Pharmaceuticals, Inc

Eagle Pharmaceuticals, Inc. Announces Resignation of Scott Tarriff as Chief Executive Officer

Eagle Pharmaceuticals, Inc. announced delayed 10-Q filing

Eagle Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Investor sentiment deteriorates as stock falls 32%

Eagle Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Founder notifies of intention to sell stock

Centers for Medicare & Medicaid Services Establishes Unique, Product-Specific Billing Code and Grants Transitional Pass-Through Payment Status for Barhemsys (Amisulpride) Injection by Eagle Pharmaceuticals, Inc

Founder notifies of intention to sell stock

Is Eagle Pharmaceuticals (NASDAQ:EGRX) A Risky Investment?

Investor sentiment deteriorates as stock falls 18%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Eagle Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Eagle Pharmaceuticals, Inc. Announces First Patient Randomized in Phase 2 Study Evaluating CAL02, A Novel First-In-Class Anti-Toxin Drug Candidate, in Severe Community-Acquired Bacterial Pneumonia

Calculating The Fair Value Of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 2000 Growth-Defensive Index

Eagle Pharmaceuticals (NASDAQ:EGRX) Seems To Use Debt Quite Sensibly

New major risk - Revenue and earnings growth

Eagle Pharmaceuticals, Inc. Receives FDA Qualified Infectious Disease Product (Qidp) and Fast-Track Designation for Cal02, Providing Five-Year Exclusivity Extension

Founder recently sold US$931k worth of stock

Founder notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates fall by 20%

Eagle Pharmaceuticals, Inc. Receives FDA Approval for Additional Indication for PEMFEXY in Combination with Pembrolizumab and Platinum Chemotherapy

Consensus forecasts updated

Insufficient new directors

Eagle Pharmaceuticals Announces FDA Acceptance of Investigational New Drug Application for CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent for the Adjunct Treatment of Severe Community-Acquired Bacterial Pneumonia

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Eagle Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 07, 2022

These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Eagle Pharmaceuticals, Inc Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CAL02

Eagle files for FDA nod to start trial of CAL02 for bacterial pneumonia

Eagle, Enalare get up to $50.3M US contract to develop ENA-001 for community drug overdose

Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS) completed the acquisition of Tyme Technologies, Inc. (NasdaqCM:TYME) from a group of shareholders.

Independent Director recently sold US$211k worth of stock

Insufficient new directors

U.S. Court of Appeals for the Federal Circuit Affirms the U.S. District Court for the District of Delaware’s Decision That Eagle Pharmaceuticals, Inc.'s Vasopressin Product Does Not Infringe on Any of the Patents Asserted by Par Pharmaceutical, Inc

Eagle Pharma did not infringe on Endo’s vasopressin patents – appeals court

Consensus revenue estimates fall by 21%

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analysts Are More Bearish Than They Used To Be

Price target decreased to US$43.00

Eagle Pharmaceuticals Non-GAAP EPS of $1.56 misses by $1.80, revenue of $74.1M misses by $42.79M

Eagle Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Michael Moran Separates as Executive Vice President, Chief Commercial Officer of Eagle Pharmaceuticals, Inc

These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Eagle Pharmaceuticals, Inc., Annual General Meeting, Jul 28, 2022

Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX) completed the acquisition of Acacia Pharma Group plc (ENXTBR:ACPH) from a group of shareholders.

Eagle Pharmaceuticals, Inc. Announces Submission of New Drug Application to U.S. Food and Drug Administration for Landiolol, A Beta-1 Adrenergic Blocker

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 42% Above Its Share Price

Now 20% undervalued

Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX) entered into an agreement to acquire Acacia Pharma Group plc (ENXTBR:ACPH) from a group of shareholders for €89.8 million.

Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX) entered into an agreement to acquire Acacia Pharma Group plc (ENXTBR:ACPH).

Eagle Pharmaceuticals, Inc. Provides Earnings Guidance for the First Quarter of 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

Eagle Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 07, 2022

Eagle Pharmaceuticals, Inc. Announces Commercial Availability of PEMFEXY™

Eagle Pharmaceuticals, Inc. on Track to Support Submission of New Drug Application in Second Quarter 2022 for Landiolol, a Beta-1 Adrenergic Blocker

Eagle Pharmaceuticals Announces Commercial Availability of Vasopressin

Eagle Pharmaceuticals, Inc. Receives 180 Days of Marketing Exclusivity for Approved Vasopressin